The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 11, 2002, Pages 23-27

  Krane, Vera ^a   Wanner, Christoph ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Atherosclerosis; Diabetes; Dyslipidaemia; Inflammation; Oxidative stress; Uraemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; LIPOPROTEIN; SUPEROXIDE;

ACUTE PHASE RESPONSE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; IMMUNOSTIMULATION; INFLAMMATION; KIDNEY DYSFUNCTION; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; UREMIA;

EID: 0036413789     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_11.23     Document Type: Article

References (56)

1. Luke RG. Chronic renal failure-a vasculopathic state. N Engl J Med 1998; 339: 841-843
2. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615
3. Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
4. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
5. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114
6. Zoccali C, Bode-Böger SM, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
7. Panichi V, Migliori M, De Pietro S et al. C-reactive protein as a marker of chronic inflammation in uremic patients. Blood Purif 2000; 18: 183-190
8. Zimmermann J, Schramm L, Wanner C et al. Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy. Clin Nephrol 1996; 46: 230-236
9. Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001; 3: 99-102
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
11. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia 1994; 37: 141-144
12. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999; 53: 580-591
13. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990; 108: 1234-1244
14. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991; 266: 4706-4712
15. Goldberg HJ, Scholey J, Fantus IG. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through SP1 DNA binding sites in glomerular mesangial cells. Diabetes 2000; 49: 863-871
16. Koya D. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447
17. Miyata T, van Ypersele de Strihou C, Kurokowa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
18. Du XL, Edelstein D, Dimmeler S el al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the AKT site. J Clin Invest 2001; 108: 1341-1348
19. Schwedler S, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301-310
20. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001; 38 [Suppl 1]: 14-19
21. Cashin-Hemphill L, Kramsch DM, Azen SP et al. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results. J Curr Clin Trials 1992; document no. 26 (erratum 1992; document no. 29)
22. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697-704
23. Hodis HN, Mack WJ, Dunn M et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022-2026
24. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 126: 262-269
25. Shoji T, Nishizawa Y, Kawagishi T et al. Intermediate density lipoproteins as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277-1284
26. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996; 276: 875-881
27. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-12226
28. Ichikawa I, Kiyama S, Yoshioka T. Renal antioxidant enzymes: their regulation and function. Kidney Int 1994; 45: 1-9
29. Witko Sarsat V, Friedlander M, Capeillere Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
30. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
31. Gunduz Z, Dusunsel R, Kose K et al. The effects of dialyser reuse on plasma antioxidative mechanisms in patients on regular hemodialysis treatment. Free Rad Biol Med 1996; 21: 225-231
32. Malle E, Woenckhaus C, Waeg G et al. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 1997; 150: 603-615
33. Hultqvist M, Hegbrant J, Nilsson-Thorell C et al. Plasma concentrations of vitamin C, vitamin E and/or malodialdehyde as markers of oxygen free radical production during hemodialysis. Clin Nephrol 1997; 47: 37-46
34. Gotoh M, Nagase S, Aoyagi K, Hirayama A et al. Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. Nephrol Dial Transplant 1997; 14: 713-717
35. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-883
36. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999; 31: 261-272
37. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-2137
38. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475-486
39. Galli F, Canestrari F, Bellomo G. Pathophysiology of the oxidative stress and its implication in uremia and dialysis. Contrib Nephrol 1999; 127: 1-31
40. Hasselwander O, Young IS. Oxidative stress in chronic renal failure. Free Radic Res 1998; 29: 1-11
41. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension. Hypertension 1999; 34: 539-545
42. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571
43. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med 2000; 28: 463-499
44. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997; 23: 140-143
45. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250: H822-H827
46. Halliwell B, Zhao K, Whiteman M. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good-a personal view of recent controversies. Free Radic Res 1999; 31: 651-669
47. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513
48. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-1083
49. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38: 1408-1413
50. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
51. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 154-160
52. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218
53. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 24: 376-379
54. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457
55. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 29: 616-622
56. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system, vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-996